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Systemic lupus erythematosus, or lupus, is a systemic
autoimmune disease characterized by the production of
autoantibodies against nuclear components. Symptoms of
lupus are varied and range from mild arthritis to renal
failure. The disease aﬀects at least 5 million people world-
wide. Despite substantial eﬀort over many years, conclusive
answers regarding the etiology, pathogenesis, and treatment
of lupus have remained elusive. However, recent research,
including genome-wide genetic and transcriptional analysis
has revealed potential roles for many diﬀerent factors. This
understanding of the disease is beginning to bear fruit with
the development of therapeutics for lupus.
With the BLyS inhibitor Belimumab poised to be the ﬁrst
treatment for lupus approved by the United States Food and
Drug Administration in decades, the potential of cytokines
in the realm of therapeutic targets for lupus is starting to be
realized. These fascinating molecules regulate multiple facets
of the immune system and, as such, have been extensively
examined for a role in many diﬀerent aspects of lupus
etiology, pathogenesis, and regulation. Given their powerful
abilities and the potential for straightforward inhibition
by biological or other pharmacological agents, multiple
cytokines may be future targets for the treatment of SLE.
A discussion of therapeutic cytokine inhibition, especially
targeting of interferon alpha, is included in this issue. Also
included is an analysis of unintended consequences of such
treatments, where targeting of a cytokine (TNF-alpha) to
treat rheumatoid arthritis can accelerate loss of tolerance
and lupus-like autoimmunity.
Cytokine dysregulation is likely to play a role in the
loss of immune tolerance that leads to lupus and in the
damage resulting from the disease. Excess interferon alpha
and interferon alpha responsive gene expression have
been identiﬁed as hallmarks of many cases of lupus. IL-10
and IL-21 are cytokines that show increased expression
in lupus, and which regulate lymphocyte development
and tolerance. Another cytokine, IL-17, is dysregulated in
lupus enhancing the pathogenesis of the disease. These
and other proinﬂammatory cytokines are likely to not only
contribute to loss of tolerance and the symptoms associate
with lupus, but they likely accelerate atherosclerosis in lupus
patients. Other cytokines, such as IL-2, are underexpressed
in lupus, with detrimental eﬀects on immune tolerance
and T-regulatory cell development. All of these roles for
cytokines in lupus are discussed in this issue.
Through the use of whole-genome screening techniques
and large study populations, understanding of the genetic
components of lupus is rapidly progressing. As cutting-edge
genetic research into the etiology of lupus progresses,
cytokines are becoming increasingly identiﬁed as genetic risk
factors. Many of the genes that are associated with risk for
lupus are cytokines, regulators of cytokines, or downstream
members of cytokine pathways. Examples of these factors
that are associated with risk for lupus and are examined in
this special issue include Interferon Alpha, Interferon Kappa,
Monocyte Chemoattractant Protein, Adiponectin, IL-10,
IL-21, and Phosphoinositide Kinase. These lupus-associated
genes are likely to contribute to the etiology of lupus, and
understanding their roles will aid in deﬁning the pathways
t h a tl e a dt ol o s so fi m m u n et o l e r a n c e .
This special issue contains work investigating many
diﬀerent facets of the relationships between cytokines and
lupus, and includes the following.
The article by D. Y. H. Yap and K. N. Lai is a review
discussing pathologically relevant cytokines ant potential
therapeutic interventions. The paper by H.-M. Lee et al.2 Journal of Biomedicine and Biotechnology
comprises an overall review of the topic covering many
cytokines and their regulation in lupus, focusing on those
that may contribute to pathogenesis. The review by M. Tucci
et al. tackles linking cytokines, T cells and kidney damage
in lupus. The review article by C. C. Mok demonstrates
the potential for cytokines and chemokines in evaluating
kidney disease in lupus. H. Okamoto et al. have written
a review evaluating the utility of cytokines as markers for
neuropsychiatric disease in lupus. The review article by C.
L´ opez-Pedrera et al. discusses cytokines in cardiovascular
disease and evaluating therapeutic options for dealing with
these cytokines. The paper by T. Hayashi outlines the role of
Th1/Th2 balance in lupus and strategies for regulating that
balance therapeutically. The article by K. H. Yoon evaluates
the calcineurin inhibitor tacrolimus as a therapeutic agent
for lupus, focusing on the eﬀects of this drug on cytokine
production. The paper titled “IL-17 in systemic lupus ery-
thematosus”b yJ .C .C r i s p ´ ı na n dG .C .T s o k o sd e s c r i b e s
the cellular sources and role of IL-17 in lupus pathogenesis,
especially in nephritic disease. A review by L. A. Lieberman
and G. C. Tsokos revolves around the aberrant production
of IL-2 and IL-2 family members in lupus. The paper titled
“Interferon alpha in systemic lupus erythematosus”b yT .B .
Niewold et al. shows the multiple mechanisms through
which interferon alpha contributes to lupus, as well as the
clinical implications of this dysregulation. M. Sarra and
G. Monteleone work supports a role for IL-21 in lupus
pathogenesis.
“Anti-TNF-α therapies in systemic lupus erythematosus”
by L.-J. Zhu et al. highlights the eﬀects of anti-TNF alpha
treatments on lupus and the role of TNF alpha in lupus
and lupus-like disease. E. Kassi and P. Moutsatsou analyze in
their review the potential role of cytokines in the increased
risk of lupus for women. L. Dong et al. examine in their
research article the correlation between lipid rafts, cytokine
expression, and lupus. Keiko Yoshimoto et al. suggest in their
research article an impairment in the regulation of TCR zeta
in lupus. The article titled “IL-10 and TNFα genotypes in
SLE”b yP .L ´ opez et al. summarizes the involvement of IL-
10 and TNFα genetic variants on SLE etiology, and clinical
relevance. W. L. Fang et al. analyze in their research article
adiponectin alleles and their relationship with risk for lupus.
In the research article by P. Piotrowski et al., we see that
they are clarifying and supporting a role for MCP1 poly-
morphisms in lupus risk. A. Kawasaki et al. conﬁrm in their
research article that TNFAIP3 is a risk factor for lupus. I. T.
W. Harley et al. identify in their research article a novel single
nucleotide polymorphism that is associated with risk for
lupus in males. S. N. Kariuki et al., in their research article,
highlight a functional consequence on the antibody proﬁle
of a promoter variant associated with risk for lupus. M. Zhao
et al. have written a research article examining epigenetic
factors on expression of important lupus-related cytokines.
Thepaper“Cytokine-inducedmonocytecharacteristicsinSLE”
by Z. Zhang et al. demonstrates epigenetic changes due to
lupus cytokines.
Cytokine research holds tremendous promise for under-
standing and treating lupus. We are grateful to all those
who contributed articles for this special issue and those who
reviewed and in other ways contributed. We hope that this
avenue of research will continue to be supported and be a
beneﬁt to the lives of those suﬀering with this complex and
diﬃcult disease.
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